The manufacturing of CAR-T and other autologous cell therapies is about to transform thanks to the innovative technology being developed by Ireland-based cell therapy company aCGT Vector. By placing PODular “GMP-in-a-POD” distributed manufacturing systems in cancer centers of excellence, complex and expensive logistical issues will be resolved, substantially lowering the cost of the novel personalised medicines and consequently enhancing patient access.

Scientific Editor in Chief for Pharma’s Almanac, David Alvaro makes an in depth analysis on how CAR-T and other autologous cell therapies can be improved and optimised.